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Abstract
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant genetic condition affecting the vascular system
and is characterised by epistaxis, arteriovenous malformations and mucocutaneous and gastrointestinal telangiectases. This
disorder affects approximately 1 in 8,000 people worldwide. Significant morbidity is associated with this condition in
affected individuals, and anaemia can be a consequence of repeated haemorrhages from telangiectasia in the gut and nose.
In the majority of the cases reported, the condition is caused by mutations in either ACVRL1 or endoglin genes, which
encode components of the TGF-beta signalling pathway. Numerous missense mutations in endoglin have been reported as
causative defects for HHT but the exact underlying cellular mechanisms caused by these mutations have not been fully
established despite data supporting a role for the endoplasmic reticulum (ER) quality control machinery. For this reason, we
examined the subcellular trafficking of twenty-five endoglin disease-causing missense mutations. The mutant proteins were
expressed in HeLa and HEK293 cell lines, and their subcellular localizations were established by confocal fluorescence
microscopy alongside the analysis of their N-glycosylation profiles. ER quality control was found to be responsible in eight
(L32R, V49F, C53R, V125D, A160D, P165L, I271N and A308D) out of eleven mutants located on the orphan extracellular
domain in addition to two (C363Y and C382W) out of thirteen mutants in the Zona Pellucida (ZP) domain. In addition, a
single intracellular domain missense mutant was examined and found to traffic predominantly to the plasma membrane.
These findings support the notion of the involvement of the ER’s quality control in the mechanism of a significant number,
but not all, missense endoglin mutants found in HHT type 1 patients. Other mechanisms including loss of interactions with
signalling partners as well as adverse effects on functional residues are likely to be the cause of the mutant proteins’ loss of
function.
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Introduction
Hereditary hemorrhagic telangiectasia or Osler-Rendu-Weber
syndrome is a genetically heterogeneous autosomal dominant
vascular disorder characterized by multiorgan vascular dysplasias,
recurrent epistaxis and mucocutaneous telangiectasia [1–3].
Prevalence of HHT is estimated to be at least 1 in 8,000 with
higher rates seen in some geographical areas [4–6].
Individuals with HHT initially present with spontaneous
recurrent nosebleeds from telangiectasia of the nasal mucosa [2],
[7], [8]. Telangiectases may also develop on the face, lips, mouth
and gastrointestinal tract leading to haemorrhage and anemia in
some cases [2,8]. Unfortunately, arteriovenous malformations
(AVMs) in the pulmonary, cerebral or hepatic circulation account
for some of the most devastating clinical complications of HHT
including stroke, fatal hemorrhages and heart failure [9].
HHT can be classified into at least two types; type 1 (HHT1;
OMIM 187300) is caused by mutations in Endoglin (ENG) gene
and type 2 (HHT2; OMIM 600376) is caused by mutations in
activin receptor-like kinase 1 (ACVRL1) gene [4], [10], [11].
Mutations in both genes account for nearly 85% of all HHT cases
while the remaining cases are caused by mutations in SMAD4 or
other yet unknown genes [11].
The protein products of ENG and ACVRL1 genes are type 1
membrane proteins and are components of the transforming
growth factor beta (TGF beta) receptor. They are involved in
intracellular signaling with biological implications on the regula-
tion of cellular proliferation, differentiation, migration and
extracellular matrix formation [12], [13]. Alk-1, the protein
product of ACVRL1 is a type 1 membrane receptor and a partner
for BMPR2 protein whereas endoglin is an accessory receptor
protein to the signaling complex [12], [14–16].
Over 700 different mutations in ENG and ACVRL1 genes have
been identified in patients with HHT1 and HHT2, respectively
[4], [11], [17] (http://www.hhtmutation.org). Endoglin is a type I
180 KDa disulphide-linked homodimer integral membrane gly-
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of 561 amino acids that consists of Zona Pellucida (ZP) and orphan
domains together forming a dome-like structure with an internal
cavity in the dimeric state. In addition, it contains a small (47
amino acid) serine threonine rich intracellular domain of unknown
function [19]. The cysteine residues in this protein are involved in
intra- and inter-subunit disulfide bridges and this suggests a tightly
folded and structured homodimer protein. The vast majority of
HHT1 causing mutations in ENG are in the extracellular domain
[4] (http://www.hhtmutation.org); this is presumably due to its
much larger size compared to the intracellular domain (Fig. 1).
We hypothesized that many of the missense mutations affecting
the disulfide bridges and other structural amino acids within the
protein are expected to result in at least partial misfolding of the
mutated proteins and subsequently their retention in the ER by
the ER quality control mechanism. This eventually leads to
degradation of these misfolded proteins by the ER-Associated
protein Degradation (ERAD) system [20, B. Ali, unpublished].
ERAD is highly stringent and harbours an elaborate quality
control mechanism for protein folding, posttranslational modifi-
cations and multisubunit complex assembly within the ER lumen
of all eukaryotic cells [21–23]. Clearly, the ER is the entry point to
the secretory pathway and therefore is the first step for almost a
third of all cellular proteins. This means that several thousand
different proteins are subjected to this highly stringent quality
control system. We and others have shown that ERAD is involved
in the cellular mechanisms of numerous human genetic conditions
including cystic fibrosis, emphysema and Robinow syndrome [20],
[24–27]. We exploited bioinformatics algorithms and databases of
disease genes to identify over 30 ERAD disease candidates where a
molecular defect consistent with protein misfolding was evident
from the position and nature of the disease-associated allele, but
significantly, where the molecular aetiology was unknown [20].
We experimentally validated this approach by the analysis of
several autosomal recessive skeletal conditions including Robinow
Syndrome [20], [27], Acromesomelic Dysplasia type Maroteaux
[28] and Sponydylo-meta-epiphyseal Dysplasia with short limbs
and abnormal calcifications (SMED-SL) [29]. In the vast majority
of cases examined, disease-causing missense mutants were shown
to be retained in the ER and degraded by ERAD. These findings
provided unequivocal support to our bioinformatics predictive
approach.
Unlike the conditions that we have examined previously, HHT1
is an autosomal dominant condition. However, it is considered to
Figure 1. The three-dimensional structure of endoglin monomer showing the locations of the twenty five missense mutants
studied in this aricle. Endoglin consists of a small c-terminal intracellular domain and three extracellular domains that include the ZP-C (green), ZP-
N (Orange) and orphan (yellow) domains. The endoglin model structure (Llorca et al. 2007) file was provided by Dr Carmelo Bernabeu and then was
manipulated using RasMol 2.7 (www.RasMol.org). The ball and stick represntation of the ER-retained (back) and the predominantly plasma membrane
(purple) mutants are indicated on the strucure. It is clear that the majority of the mutants affecting the orphan domain resulted in the retention of the
protein in the ER whereas those affecting the ZP domains retained their plasma membrane localization.
doi:10.1371/journal.pone.0026206.g001
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nature and the haploinsufficiency effects of the causative mutations
[30], [31]. In this article, we examine the trafficking of a significant
number of missense mutations in endoglin that are found in
HHT1 patients and demonstrate that retention in the ER by the
ER quality control system significantly contributes to the cellular
mechanism of this condition.
Results
Mutations in the orphan domain of endoglin are
predominantly localized to the endoplasmic reticulum
Structural modelling of the extracellular domains of the human
endoglin protein revealed two major domains, an orphan N-
terminal domain that comprise residues Glu26-Ile359 and ZP
domain that comprises residues Gln360-Gly586 [19]. The
predicted orphan domain structure does not show significant
homology to any known family of proteins. However, an excess of
150 different mutations within this domain, including many
missense mutations, have been shown to cause HHT1 (http://
www.hhtmutation.org). Indeed, 21 out the 33 missense mutations
modelled by Llorca et al [19] are located in the orphan domain
and the vast majority of them are conserved within different
species. Reduced or absence of cell surface expression of some
HHT1 causing mutants have been reported previously [4].
However, the underlying mechanism of this reduced expression
and the overall mechanism of HHT1 have not been fully
established. In addition, we previously hypothesized that the ER
quality control might be contributing to the cellular mechanisms of
HHT [20, B. Ali, unpublished].
Randomly selected missense mutants (L32R, V49F, C53R,
V125D, W149C, A160D, P165L, D264N, I271N, A308D and
V311G) within the orphan domain were generated by site directed
mutagenesis. Their cellular localization by confocal fluorescence
microscopy and sensitivity to endoglycosidase H (Endo H)
treatment was also established. We show that eight of the eleven
mutations resulted in the mislocalization of endoglin to the ER
rather than to the plasma membrane. As shown in the confocal
microscopy images in figure 2, the wild type endoglin is
predominantly localized to the plasma membrane as evidenced
by its co-localization with GFP-hRas. The partial localization with
the ER marker (calnexin) is most likely indicative of the in transit
newly synthesized endolglin population. Alternatively, many wild
type secretory proteins that fail to fold properly are retained in the
ER for some time to allow folding to take place. On the other
hand, the missense mutants L32R, C53R, V125D, P165L and
I271N are predominantly co-localized with calnexin and were
absent from the plasma membrane (Fig. 2 and 3). In addition, the
following mutants V49F, A160D and A308D co-localized with
calnexin in the ER and were excluded from the plasma membrane
(confocal microscopy images not shown). Only W149R, D264N
and V311G mutants were found to be localized to the plasma
membrane in a pattern reminiscent to the wild type endogin (data
not shown).
To further confirm the subcellular localization of the generated
mutants mentioned above, we performed Endo H sensitivity and
resistance in vitro assays on the expressed proteins. Endoglin is a
highly glycosylated protein with several potential N-glycosylation
sites in its extracellular domain [18], [19]. The premise of this
assay is that the carbohydrate moieties of the ER-localized
glycoproteins are cleavable by Endo H whereas the post-ER
species will be resistant due to further remodelling in the Golgi
complex of their N-glycans.
We performed the Endo H assay on immuneprecipitated wild
type and mutants proteins expressed in HEK293 cells as described
in the method section. As expected, we found that a proportion of
the wild type protein is resistant to Endo H treatment and
confirms that the wild type protein targets largely to the plasma
membrane (Fig. 4) as observed in figures 2 and 3. On the other
hand, mutants L32R, V49F, C53R, V125D, A160D, P165L,
I271N and A308D showed a single lower molecular weight protein
band after Endo H treatment and thus confirming their retention
in the ER and failure to pass through the Golgi complex (Fig. 4).
Three mutants that appeared to localize predominantly to the
plasma membrane (W149R, D264N and V311G) behaved in a
similar manner to the wild type upon Endo H treatment.
Summary of the confocal microscopy and Endo H assay data is
summarized in table 1.
Mutations in the ZP and the intracellular domains of
endoglin are predominantly localized to the plasma
membrane
The other domains of endoglin are the ZP extracellular domain,
which can be divided into ZP-N and ZP-C sub-domains, the 25
hydrophobic residue transmembrane domain (Leu587-Trp611)
and the intracellular domain [19]. The ZP-N domain comprises
residues Gln360-Ser457 and ZP-C residues Pro458-Gly586. The
intracellular cytoplasmic domain consist of 47 amino acids rich in
serine and threonine residues of which three are constitutively
phosphorylated [18], [32]. In a similar manner to the orphan
domain, more than 150 different mutations, including many
missense mutations, in the ZP domain have been identified in
patients with HHT1. In contrast, only a couple of mutations have
been reported within the small intracellular domain.
We generated 13 missense mutations in the ZP domain and one
mutation in the intracellular domain and we then evaluated the
effects of these mutations on the intracellular localization of the
mutated proteins, using either or both confocal microscopy and
Endo H treatment analysis as described in the materials and
methods section. The single intracellular missense mutation
(S615L) had no effect on subcellular localization of the protein
being predominantly localized to the plasma membrane in a
similar pattern to wild type (data not shown). Similarly, the vast
majority of ZP mutants examined (C382G, F403S, S407N,
C412S, G413V, N423S, R437W, A452G, Q476H, V504M and
R571H) behaved in a similar manner. Figure 5 illustrates
representative examples of confocal images and figure 4 shows
the Endo H treatment results. The only exceptions were C363Y
and C382W mutants that co-localized with the ER marker (data
not shown). The Endo H treatment results (Fig. 4) of these mutants
confirmed the microscopy images.
Discussion
HHT is an autosomal dominant condition affecting nearly 1 in
8,000 people worldwide. Complications associated with HHT can
be serious, leading to significant morbidity and in some cases
mortality. There is no cure for this condition and therefore there is
an urgent need to search for effective treatments. Developing new
avenues for therapy is likely to benefit from detailed understanding
of the molecular and cellular basis of this condition. The main
causes of HHT include mutations in ENG, the gene encoding
endoglin which is an essential component of the TGF beta
signaling machinery [33], [34].
In addition, haploinsufficiency has been proposed to be the
most commonly accepted pathogenic model for HHT. Endoglin
plays key roles in cardiovascular development, angiogenesis and
Cellular Mechanism of Endoglin Mutations in HHT1
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missense endoglin mutations led to reduced or loss of cell surface
expression of the mutant proteins [31,35,36]. However, the nature
of the loss of cell surface expression and the universality of this
mechanism to other missense mutations has not been established.
In this manuscript, we examined the subcellular trafficking and
targeting of twenty five endoglin missense mutations found in
HHT1 patients [4], [11], [17], [37] (http://www.hhtmutation.
org). The examined missense mutations have been selected
randomly and distributed along the protein structure including
the small intracellular domain and the two large extracellular
domains (the orphan and ZP domains). By means of electron
microscopy and atomic modeling, Llorca et al [19] have
determined a low resolution (25 Angstrom) three-dimensional
structure of the extracellular domain of endoglin. They have found
that the extracellular domain is arranged in a dome-like structure
enclosing a cavity made of antiparallel oriented monomers each
composed of three domains. The domain and structural locations
of the studied missense mutations in this manuscript are shown in
figure 1.
Subcellular localization of most of the missense mutations
affecting the orphan domain resulted in the misfolding and
presumably their retention by the ER quality control machinery
(Fig. 2, 3, and 4). This domain has no structural similarities to
other protein domains. However, from the ab initio low resolution
three-dimensional model determined by Llorca et al [19], it is
clear that this domain adopts a defined compacted structure with
potential intramolecular disulphide bridges. Therefore, it is
Figure 2. Comparison of the subcellular localization of wild type Endoglin with two (L32R and C53R) orphan domain HHT1-causing
mutants. HeLa cells were transiently transfected with the C-terminally HA-tagged Endoglin pCMV5 plasmids (panels A-C, G-I and M-O) or co-
transfected with the same plasmids and the EGFP-tagged H-Ras plasmid (Panels D–F, J–L and P–R) and processed for fluorescence confocal
microscopy as described in the methods. The HA tagged proteins were detected with Anti-HA monoclonal antibodies (red panels A, D, G, J. M and P)
and the ER marker calnexin was detected with anti-calnexin polyclonal antibodies (panels B, H and N). GFP-H-Ras staining is shown in panels E, K and
Q. The wild type predominantly showed plasma membrane localization as evidenced by its co-localization with Ras (D–F). On the other hand the two
mutants (L32R and C53R) showed ER localization (G–R).
doi:10.1371/journal.pone.0026206.g002
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domain might lead to its improperly folded proteins, with
subsequent retention in the ER, followed by ERAD.
As detailed in the introduction, ERAD is the main quality
control mechanism operating at the entry point of the
secretory pathways and therefore is responsible for ensuring
the quality of almost a third of all the cellular proteins [20–23].
The first steps in ERAD are the recognition of the proteins as
misfolded or malfolded followed by their retention within the
ER lumen. In addition, this quality control machinery has
been shown to be responsible for the mechanism of a large
number of human genetic conditions [20,24–26]. HHT is an
ERAD disease candidate that has been identified using genetic
disease databases and bioinformatics tools [20]. This was based
on the nature of the missense mutations in ALK1- and
endoglin that are causing HHT. In addition, it was clear from
cellular studies that some of the missense mutants reduced or
abolished the cell surface expression of the proteins [30], [31],
[35], [38]. However, the retention within the ER and the
involvement of ERAD has not been clearly established for
these mutants.
Our data clearly implicate retention in the ER as a major
mechanism of HHT1 missense mutants especially those harboring
mutations in the orphan domain. The HHT1-causing missense
mutants in endoglin that traffic to plasma membrane are likely to
be causing the condition by different mechanisms including the
loss of their ability to interact with partners or loss of their ability to
activate the signaling pathways. It is also possible that the
trafficking of those mutants is attenuated in comparison to the
wild type protein thus compromising the protein biological
function. However, we have no data at this stage to support the
exact mechanisms of those mutants.
Figure 3. The subcellular localization of three orphan domain HHT1-causing mutants (V125D, P165L and I271N). HeLa cells were
transiently transfected with the C-terminally HA-tagged Endoglin pCMV5 plasmids (panels A–C, G–I and M–O) or co-transfected with the same
plasmids and the EGFP-tagged H-Ras plasmid (Panels D–F, J–L and P–R) and processed for fluorescence confocal microscopy as described in the
methods. In all three cases, the mutants co-localized with the ER marker (A–C for V125D; G–I for P165L and panles M–O for I271N) but not to the
plasma membrane (D–F, J–L and P–R for V125D, P165L and I271N, respectively).
doi:10.1371/journal.pone.0026206.g003
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disease management and possibly developing new therapies. It has
been recently proposed and shown in principle that manipulating
ER-quality control and ERAD might be a feasible drug target for
genetic diseases [39–46]. The realization, that some ER retained
proteins might be biologically functional if they were given the
opportunity to escape from this organelle has encouraged the
search for manipulation of ERAD in ways to offer a therapeutic
advantage in diseased states. This could be true for some of the
endoglin missense mutants shown to be retained in the ER in the
current study.
Materials and Methods
Chemicals and Reagents
Bovine serum albumin was obtained from Fisher Scientific
(Loughborough, UK). Endoglycosidase H (Endo H) was pur-
chased from New England Biolabs (Hertfordshire, UK). The
antibodies and their sources were as follows: Antibodies for
immunofluorescence: mouse anti-HA-Tag monoclonal antibody
(dilution 1:200; Cell Signaling Technology), rabbit anti-calnexin
polyclonal antibody (dilution 1:500; StressGen Biotechnologies),
Alexa Fluor 568-goat anti-mouse IgG (dilution1:200; Molecular
Probes), Alexa Fluor 488-goat anti-rabbit IgG(dilution 1:200;
Molecular Probes). Secondary antibodies for Western blotting
were as follows: rabbit-anti-goat Ig-horseradish peroxidase (Zymed
Laboratories Inc., San Francisco, CA); sheep-anti-mouse Ig-
horseradish peroxidase (Amersham Biosciences UK, Chalfont St
Giles, UK).
Construction of the HA-tagged Endoglin construct
The HA-tagged version of the wild-type endoglin was generated
by sequential site-directed mutagenesis to introduce the nine
amino acids of the HA tag (YPYDVPDYA) in two cycles using
pCMV5-ENG as a template (a kind gift of Professor Michelle
Letarte, University of Toronto, Canada). In the first cycle five
amino acids (YPYDV) of the HA tag were introduced prior to the
stop codon of the Endoglin gene using the following mutagenesis
primers.
ENG-HA1-F: ccagcagcatggcatacccatacgatgtttagccccggccc
ENG-HA1-R: gggccggggctaagcgtaatctggaacatcgtatgggta
In the second cycle, the above construct was used as a template
and the remaining four amino acids (PDYA) of the HA tag were
introduced using the following mutagenesis primers.
ENG-HA2-F: tacccatacgatgttccagattacgcttagccccggccc
ENG-HA2-R: gggccggggctaagcgtaatctggaacatcgtatgggta
Generation of missense Endoglin mutants
The missense mutants were introduced by QuickChange site-
directed mutagenesis with Turbo Pfu polymerase (Stratagene) and
using the C-terminally HA-tagged Endoglin as templates. The
primers for the site-directed mutagenesis to introduce the missense
mutants are as follows with the mutagenic nucleotide in bold and
underlined:
ENG-L32R- F: 59GTCCATTGTGACCGTCAGCCTGTG-
GG39
ENG-L32R- F: 59CCCACAGGCTGACGGTCACAATGGA-
C39
Figure 4. Endoglycosidase H (EndoH) analysis of the expressed missense mutants. The pCMV5 HA-tagged endoglin plasmids were
transfected into HEK293 cells and were allowed to express the proteins as described in the methods. This was followed by lysis of the cells and the
immuoprecipitation of the proteins with anti-HA monoclonal antibodies. Each immunoprecipitate was divided into two sample with one of them was
treated (+) with EndoH or left untreated (2). Both samples were then electrophorese and western blotted using anti-HA monoclonal antibodies as
described in the methods section. The majority of the WT protein did not change mobility upon EndoH treatment indicating its maturation and
acquisition of complex N-glycan moieties in the post ER compartments. The missense mutants L32R, V49F, C53R, V125D, A160D, P165L, I271N,
A308D, C363Y and C382W showed a single band indicating an exclusively ER premature forms. The other mutants either showed two bands or a
simple high molecular weight band indicating that at least a significant proportion of the expressed protein matured in post ER compartments. The
EndoH treatment data are in agreement with the confocal microscopy data.
doi:10.1371/journal.pone.0026206.g004
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GGGCTGCGTG39
ENG-V49F-R: 59CACGCAGCCCTTCGAGAACTGGCTA-
GTGGTATATG39
ENG-C53R-F: 59GGTCTCGAAGGGCCGCGTGGCTCA-
GGCCC39
ENG-C53R-R: 59GGGCCTGAGCCACGCGGCCCTTCG-
AGACC39
ENG-V125D-F: 59GTAAACAGCAGTGACTTCCTGCAT-
CTCC39
ENG-V125D-R: 59GGAGATGCAGGAAGTCACTGCTGT-
TTAC39
ENG-W149C-F: 59GATCCTTGAGTGCGCAGCTGAGAG-
G39
ENG-W149C-R: 59CCTCTCAGCTGCGCACTCAAGGAT-
C39
ENG-A160D-F: 59CATCACCTCTGCTGATGAGCTGAA-
TGACC39
ENG-A160D-R: 59GGTCATTCAGCTCATCAGCAGAGG-
TGATG39
ENG-P165L-F: 59GAGCTGAATGACCTCCAGAGCATCC-
TCC39
ENG-P165L-R: 59GGAGGATGCTCTGGAGGTCATTCA-
GCTC39
ENG-D264N-F: 59GTCCTGGCTCATCAACGCCAACCA-
CAAC39
ENG-D264N-R: 59GTTGTGGTTGGCGTTGATGAGCCA-
GGAC39
ENG-I271N-F: 59 CACAACATGCAGAACTGGACCACTG-
GAG 39
ENG-I271N-R: 59CTCCAGTGGTCCAGTTCTGCATGT-
TGTG39
ENG-A308D-F: 59CCGGATGCTCAATGACAGCATTGT-
GGCATC39
ENG-A308D-R: 59GATGCCACAATGCTGTCATTGAGC-
ATCCGG39
ENG-V311G-F: 59CAATGCCAGCATTGGGGCATCCTT-
CGTG39
ENG-V311G-R: 59CACGAAGGATGCCCCAATGCTGGC-
ATTG39
ENG-C363Y-F: 59GATCCAGACAAAGTATGCCGACGAC-
GCC39
ENG-C363Y-R: 59GGCGTCGTCGGCATACTTTGTCTG-
GATC39
ENG-C382G-F: 59GCGCATTTGAAGGGCACCATCACG-
G39
ENG-C382G-R: 59CCGTGATGGTGCCCTTCAAATGCG-
C39
ENG-C382W-F: 59CGCATTTGAAGTGGACCATCACGG-
GC39
ENG-C382W-R: 59GCCCGTGATGGTCCACTTCAAATG-
CG39
ENG-F403S-F: 59GGGGTGACAAGTCTGTCTTGCGCA-
G39
ENG-F403S-R: 59CTGCGCAAGACAGACTTGTCACCC-
C39
ENG-S407N-F: 59GTTTGTCTTGCGCAATGCTTACTCC-
AGCTG39
ENG-S407N-R: 59CAGCTGGAGTAAGCATTGCGCAAG-
ACAAAC39
ENG-C412S-F: 59GCTTACTCCAGCAGTGGCATGCAG-
G39
ENG-C412S-R: 59CCTGCATGCCACTGCTGGAGTAAG-
C39
ENG-G413V-F: 59TACTCCAGCTGTGTCATGCAGGTG-
TCAG39
ENG-G413V-R: 59CTGACACCTGCATGACACAGCTGG-
AGTA39
ENG-N423S-F: 59GTATGATCAGCAGTGAGGCGGTGG-
TC39
ENG-N423S-R: 59GACCACCGCCTCACTGCTGATCATA
39
ENG-A425G-F: 59GATCAGCAATGAGGGGGTGGTCAA-
TATCC39
ENG-A425G-R: 59GGATATTGACCACCCCCTCATTGC-
TGATC39
ENG-R437W-F: 59GCTCATCACCACAGTGGAAAAAGG-
TGCAC39
ENG-R437W-R: 59GTGCACCTTTTTCCACTGTGGTGA-
TGAGC39
ENG-Q476H-F: 59GAGCTTTGTGCACGTCAGAGTGTC-
CC39
ENG-Q476H-R: 59GGGACACTCTGACGTGCACAAAGC-
TC39
ENG-V504M-F: 59GAGGGAGGCACCATGGAACTCATC-
CAGG39
Table 1. Summary of the subcellular localization of the
missense mutants described in this study.
Mutant Domain
Experimental
localization*
Wild type None Predominantly PM
L32R Orphan Domain ER
V49F Orphan Domain ER
C53R Orphan Domain ER
V125D Orphan Domain ER
W149C Orphan Domain Predominantly PM
A160D Orphan Domain ER
P165L Orphan Domain ER
D264N Orphan Domain Predominantly PM
I271N Orphan Domain ER
A308D Orphan Domain ER
V311G Orphan Domain Predominantly PM
C363Y ZP-N Domain ER
C382G ZP-N Domain Predominantly PM
C382W ZP-N Domain ER
F403S ZP-N Domain Predominantly PM
S407N ZP-N Domain Predominantly PM
C412S ZP-N Domain Predominantly PM
G413V ZP-N Domain Predominantly PM
N423S ZP-N Domain Predominantly PM
A425G ZP-C Domain Predominantly PM
R437W ZP-N Domain Predominantly PM
Q476H ZP-C Domain Predominantly PM
V504M ZP-C Domain Predominantly PM
R571H ZP-C Domain Predominantly PM
S615L Intracellular Domain Predominantly PM
*Subcellular localization have been established by confocal microscopy and/or
Endo H analysis.
doi:10.1371/journal.pone.0026206.t001
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CCTC39
ENG-R571H-F: 59GGACTGTCTTCATGCACTTGAACA-
TCATCAG39
ENG-R571H-R: 59CTGATGATGTTCAAGTGCATGAAG-
ACAGTCC39
ENG-S615L-F: 59CTGGTACATCTACTTGCACACGCGT-
TCC39
ENG-S615L-R: 59GGAACGCGTGTGCAAGTAGATGTA-
CCAG39
All constructs were confirmed by direct DNA sequencing of the
purified plasmids.
DNA Sequencing
Sequencing was performed using the dideoxy method by
fluorescent automated sequencing on the ABI 3130xl genetic
analyzer (Applied Biosystems, Foster City, USA). The sequence
data were analysed using Sequencing analysis software v5.3 (ABI,
Foster City, USA).
Cell culture and transfection
HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf serum,
2 mM L-glutamine and 100 U/ml penicillin/streptomycin at
37uC with 10% CO2. For transfection, cells were grown on sterile
Figure 5. The majority of the missense mutants in the ZP and intraceullar domains traffic normally to the plasma membrane. HeLa
cells were transiently co-transfected with the C-terminally HA-tagged Endoglin pCMV5 plasmids and the EGFP-tagged H-Ras plasmid and 24 hours
later the cells were processed for fluorescence confocal microscopy as described in the methods. The following missense mutanst were shown to
traffic predominantly to the plama membrane as eviednced by their co-localization with GFP-H-Ras: C382G ( data not shoiwn due to space
limitations), F403S (panles A–C), S407N (not shown), C412S (not shown), G413V (not shown), N423S (panels D–F), R437W (not shown), A452G (not
shown), Q476H (not shown), V504M (panels J–L), R571H (panels M–O ) and P615L (panels P–R).
doi:10.1371/journal.pone.0026206.g005
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performed after 24 h using the liposomal transfection reagent
FuGENE (HD Reagent, Promega, USA)according to manufac-
turer’s instructions. For each well, 0.55 mg of the Endoglin wild
type and the mutant constructs were used to transfect the cells.
Twenty four hours after transfection, the cells were fixed and
processed for microscopy.
Human embryonic kidney (HEK) 293 cells (ATCC, Manassas,
VA) were cultured in Dulbecco’s modified Eagle’s medium/F12
medium (Invitrogen) supplemented with 10% fetal bovine
serum(FBS) (Sigma Chemical Co, MO, USA), penicillin (10
units/ml) and streptomycin (100 mg/ml) at 37uC in a humidified
atmosphere of 5% CO incubator. One day before transfection,
cells were seeded on six multiwells (Ø35 mm) and grown to 70%
to 80% confluency. Transfection was performed, using FuGENE
HD Transfection Reagent (Promega, USA) according to the
manufacturer’s instructions. Cells cultured were transfected with
2 mg of Endoglin wild-type or mutant plasmid DNAs.
Immunohistochemistry
For immunofluorescence, cover slip-grown HeLa cells were
washed with phosphate-buffered saline (PBS), fixed by methanol at
220uC for 4 minutes. Fixed cells were then washed in PBS three
times and incubated in blocking solution (1% BSA in PBS) for
30 min at room temperature. The fixed cells were then incubated
for 1 h at room temperature with either mouse monoclonal anti-
HA antibodies alone or co-incubated with rabbit polyclonal anti-
calnexin antibodies. After washing with PBS, the cells were
incubated with the appropriate fluorescently-labelled secondary
antibodies for 1 h at room temperature then washed several times
with PBS and mounted in immunofluor medium(ICN Biomedi-
cals). We used EGFP-hRas as a marker for the plasma membrane.
The H-Ras in this case was co-tansfected with the endoglin
construct. Data were acquired using a Nikon confocal microscope
1(Japan). For presentation purposes, images were pseudo colored
as either red (Endoglin) or green (calnexin and EGFP-H-Ras),
contrast enhanced and overlayed using Adobe PhotoshopH (Adobe
Inc.). All images presented are single sections in the z-plane.
Protein extraction and Immunoprecipitation
Immuoprecipitation was used to isolate the expressed Endoglin
from cell lysates of HEK293 cells. Forty eight hours post-
transfection of cell transfection, culture media was removed and
cells were gently washed twice with ice cold PBS (Phosphate-
buffered saline). After washing, 150 mlo f1 6ice-cold lysis buffer
(Cell-Lytic Mcell Sigma C2978 lysis reagent) containing protease
inhibitors (SIGMAFAST
TM Protease Inhibitor Cocktail Tablets,
EDTA-Free; Sigma S8830) was added to the 3.5 cmPetri dishes
and incubated on ice for 5 min. Cells were then scraped off the
plate and transferred to microcentrifuge tubes and kept on ice for
15 min.The cell lysates were then centrifuged at 14000 g for
15 min at 4uC.The supernatants were then transferred to a new
tube without disturbing the pellet. Protein was quantified by Pierce
Bicinchoninic Acid protein Assay kit according to the manufac-
turer’s instructions. Ten microliters of protein A was added to
100 ml of cell lysate and incubated on a rotator for 45 min at 4uC.
After centrifugation at 2500 g for 3 min the supernatant was
transferred to a fresh 1.5 ml tube taking care not to transfer any
beads slurry. Then 1 ml of anti-HA antibodies were added to the
supernatants and incubated at 4uC on a rotator for 3 h then 10 ml
of protein A (pre equilibrated in the corresponding IP lysis buffer)
was added and incubated at 4uC for 2 h to capture the immune
complex. The tubes were centrifuged at 2500 g for 30 s at 4uC
and the supernatant was carefully removed and the beads were
washed once with 100 ml of cold lysis buffer.
Endoglycosidase H Digestion
After immunoprecipitation, 10 ml of protein A-Sepharose beads
containing the immune complex (Endoglin and anti HA antibody)
was diluted by adding 10 ml of water. Then 5 ml of sodium
phosphate buffer (250 mM, pH 5.5) and 1.25 ml of denaturation
(containing 2%SDS and 1 M 2-mercaptpethanol, Sigma product
number S4927) solution added to each sample. Samples were then
denatured by heating at 100uC for 5 min. After cooling, 2 mlo f
Endoglycosidase H (Sigma, Saint Louis, USA) was added to each
sample and incubated at 37uC for 3 h. The cleavage products
were subjected to SDS-PAGE and western blotting using anti-HA
antibodies as described below.
Western blotting analysis
Thirty mg of protein from control (untransfected cell), endoglin
wild type and mutant constructions were subjected to15% SDS-
polyacrylamide gel and transferred tonitro cellulose membrane.
After 1 h blocking in 5% BSA (Bovine Serum Albumin),
nitrocellulose blots were incubated overnight with anti-HA
antibody (1:1000, Santa Cruz Biotechnology).Following washing
with TRIS-buffered saline/Tween-20 (0.05%), membranes were
incubated with goat anti-mouse IgGHRP (1:50000, Santa Cruz
Biotechnology)for 1 h and developed according to standard
procedures.
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